221 related articles for article (PubMed ID: 23943184)
1. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.
Mauskopf J; Chirila C; Graham J; Gersten ID; Leather H; Maziarz RT; Baden LR; Bolaños-Meade J; Brown JM; Walsh TJ; Horowitz MH; Kurtzberg J; Marr KA; Wingard JR
Am J Health Syst Pharm; 2013 Sep; 70(17):1518-27. PubMed ID: 23943184
[TBL] [Abstract][Full Text] [Related]
2. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.
Zhao YJ; Khoo AL; Tan G; Teng M; Tee C; Tan BH; Ong B; Lim BP; Chai LY
Antimicrob Agents Chemother; 2016 Jan; 60(1):376-86. PubMed ID: 26525782
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ
Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.
de la Cámara R; Jarque I; Sanz MA; Grau S; Casado MA; Sabater FJ; Carreras E
Bone Marrow Transplant; 2010 May; 45(5):925-32. PubMed ID: 19802030
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation.
Sánchez-Ortega I; Patiño B; Muñoz C; Arnan M; Peralta T; Clopés A; de Sevilla AF; Duarte RF
J Med Econ; 2013; 16(6):736-43. PubMed ID: 23541251
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease.
O'Sullivan AK; Weinstein MC; Pandya A; Thompson D; Langston AA; Perfect JR; Papadopoulos G
Am J Health Syst Pharm; 2012 Jan; 69(2):149-56. PubMed ID: 22215361
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
[TBL] [Abstract][Full Text] [Related]
8. Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.
Athanasakis K; Petrakis I; Kyriopoulos J
J Med Econ; 2013; 16(5):678-84. PubMed ID: 23448409
[TBL] [Abstract][Full Text] [Related]
9. [Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico].
Rely K; Alexandre PK; Escudero GS
Value Health; 2011; 14(5 Suppl 1):S39-42. PubMed ID: 21839897
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
Lundberg J; Höglund M; Björkholm M; Åkerborg Ö
Clin Drug Investig; 2014 Jul; 34(7):483-9. PubMed ID: 24820968
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
[TBL] [Abstract][Full Text] [Related]
12. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis.
Dranitsaris G; Khoury H
Support Care Cancer; 2011 Nov; 19(11):1807-13. PubMed ID: 20972589
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Grau S; Cámara R; Jurado M; Sanz J; Aragón B; Gozalbo I
Eur J Health Econ; 2018 May; 19(4):627-636. PubMed ID: 28569350
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of voriconazole, fluconazole, and amphotericin B for invasive fungal infections following allogeneic hematopoietic stem cell transplantation in Mexico.
Morfín-Otero R; Alvarado-Ibarra M; Rodriguez-Noriega E; Resendiz-Sanchez J; Patel DA; Stephens JM; Di Fusco M; Mendoza CF; Charbonneau C
Clinicoecon Outcomes Res; 2018; 10():511-520. PubMed ID: 30233223
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomics of voriconazole in the management of invasive fungal infections.
Al-Badriyeh D; Heng SC; Neoh CF; Slavin M; Stewart K; Kong DC
Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):623-36. PubMed ID: 21155694
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States.
O'Sullivan AK; Pandya A; Papadopoulos G; Thompson D; Langston A; Perfect J; Weinstein MC
Value Health; 2009; 12(5):666-73. PubMed ID: 19508661
[TBL] [Abstract][Full Text] [Related]
20. Adapting a global cost-effectiveness model to local country requirements: posaconazole case study.
Papadopoulos G; Hunt S; Prasad M
J Med Econ; 2013; 16(3):374-80. PubMed ID: 23256900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
